Medical Oncologist
CION Cancer Clinics
IDH1 mutations in bile duct cancer: what they mean for treatment | CION Cancer Clinics
An IDH1 mutation is a fault inside some bile duct cancer cells, most often in cancer that starts in the small ducts inside the liver. It matters because a targeted tablet, ivosidenib, can be an option after the usual first treatment. This page explains how the fault is found, where the tablet fits, who it does not suit, and what to ask your oncologist. At CION Cancer Clinics in Hyderabad, our oncologists explain liver cancer in plain words and plan care around you and your family.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does an IDH1 mutation mean for bile duct cancer treatment?
- How does an IDH1 result change the plan?
- How do doctors find out if a tumour has an IDH1 mutation?
- What do the words on a molecular report mean?
- Who is an IDH1 tablet not right for?
- What this page cannot tell you
- Common questions about IDH1 in bile duct cancer
The short answer
What does an IDH1 mutation mean for bile duct cancer treatment?
An IDH1 mutation is a fault found inside the tumour cells of some bile duct cancers, most often the kind that starts inside the liver. It matters because there is a tablet, ivosidenib, designed to block the faulty IDH1 protein, and it can be a treatment option after the usual first treatment.
Which cancer this page is about
This page is about intrahepatic cholangiocarcinoma, a primary cancer of the small bile ducts inside the liver. It is not about cancer that spread to the liver from the bowel, breast or elsewhere. If your report says metastasis or secondary, read the page on why cholangiocarcinoma is mistaken for secondary cancer first.
What the result does and does not do
Finding IDH1 does not make the cancer milder or more serious on its own. It adds one more option to the list your oncologist can use. Most people with this mutation still start on the standard combination of chemotherapy and immunotherapy. The targeted tablet usually comes in later, if the cancer grows again.
An IDH1 mutation is found in the tumour. It is not inherited, and your children do not need testing for it.What the team weighs
How does an IDH1 result change the plan?
The result is one input. The tumour board weighs it alongside the stage, your liver and your strength.
If the tumour can be removed
Surgery is still the main treatment that offers a chance of a long-term answer. The IDH1 result does not replace an operation. It is filed for later, in case the cancer returns.
If it cannot be removed
First treatment is usually gemcitabine and cisplatin with an immunotherapy medicine. Ivosidenib is generally considered when that stops working or cannot be continued.
How you are coping
A tablet taken at home suits some people better than drips in a day unit. Your strength, other illnesses and how your liver is working all shape whether a targeted medicine is sensible.
The team also checks
- Bilirubin and whether a stent is draining bile well
- Heart rhythm, since some medicines affect it
- Every other medicine you take
Whether you can get it
Access to ivosidenib in India is limited and changes. Your oncologist will tell you whether it can be obtained, imported or reached through a clinical trial at the time you need it.
Not sure whether this applies to you?
Ask an oncologistHow it is found
How do doctors find out if a tumour has an IDH1 mutation?
A tissue sample is needed
The test is done on tumour tissue, usually from the biopsy that confirmed the diagnosis. CION arranges the biopsy through partner hospitals and diagnostic partners. The biopsy and scan pages explain how it is taken.
A broad gene panel is run
Rather than testing one gene at a time, a laboratory reads many genes at once. This is called next-generation sequencing. It looks for IDH1, FGFR2 and other faults in a single test, which saves tissue.
A blood test is sometimes used
If there is too little tissue, a blood test that picks up tumour DNA can help. A negative blood result does not always rule a mutation out, so tissue is preferred.
The tumour board reads the result
The report goes to the multidisciplinary team, who decide whether the mutation changes the plan now or later. You should be told the result in plain words and given a copy.
On your report
What do the words on a molecular report mean?
- IDH1
- A gene that makes an enzyme used for energy inside the cell. When it is faulty, the cell makes a substance that can push it towards cancer.
- R132 (for example R132C)
- The exact spot where the fault sits in the gene. It is a label for the laboratory, not a stage or a grade.
- Somatic
- Found only in the tumour, not in the rest of your body. It cannot be passed on to children.
- Actionable
- There is a medicine designed for this fault. It does not mean the medicine will work for you, only that it exists.
- Ivosidenib
- A tablet that blocks the faulty IDH1 enzyme. The IDH1 targeted therapy page covers how it works and its side effects.
- IDH2
- A related gene. It is less common in bile duct cancer and is not treated with the same tablet.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Did you know
IDH1 is one of several faults worth looking for in bile duct cancer. FGFR2, HER2, BRAF and MSI can each open a different option, which is why one broad test is better than checking a single gene.
Who this does not suit
Who is an IDH1 tablet not right for?
Ivosidenib only makes sense if the tumour actually carries an IDH1 mutation. Without a confirmed result, it should not be used, however hopeful the family feels. It is also not the right first choice for most people, because the standard chemotherapy and immunotherapy combination comes first.
When the body is too weak
Someone who spends most of the day in bed, or whose liver is failing, may be harmed more than helped by any cancer medicine. In that situation, good symptom care is often the kinder plan, and choosing it is not giving up.
When the tumour can still be removed
The tablet does not replace surgery for a tumour your surgeon can take out. CION's surgical oncologists assess whether an operation is possible, and your team will tell you where it would take place.
Setting fair expectations
For people who benefit, the tablet tends to slow the cancer and hold it steady for a while. It rarely shrinks it dramatically, and it is not a way to make the cancer disappear. Ask what a good response would look like for you.
Being straight with you
What this page cannot tell you
It cannot tell you whether your tumour carries an IDH1 mutation. Only a laboratory test on the tissue or blood can do that. It also cannot tell you whether the tablet will work for you, how long it might help, or what it will cost where you are being treated.
Who can answer
Your medical oncologist can read your molecular report alongside your scans and blood tests. If testing was never done, ask whether stored biopsy tissue can still be sent. If you already have a report and a plan and want another view, a second opinion can review both.
Bring the full molecular report, not just the summary page, to every appointment.Questions we are asked
Common questions about IDH1 in bile duct cancer
Is an IDH1 mutation good or bad news?
Neither, on its own. It does not set how fast the cancer grows or how it will behave. What it does is add a targeted option your oncologist can keep in reserve. Many families find that knowing a further option exists makes the next conversation a little easier.
Can my children inherit an IDH1 mutation?
No. In bile duct cancer, IDH1 faults arise inside the tumour during life and are not present in the rest of the body. They are not passed down a family. If your report mentions a germline or inherited finding, that is a separate question for a genetic counsellor.
Should every bile duct cancer be tested for IDH1?
Bile duct cancers should have their DNA tested, ideally with a broad panel that looks at IDH1 and the other faults together. Testing does not promise a targeted option. It makes sure one is not missed. Read why molecular testing matters for more.
Will I start the tablet straight away?
Usually not. For most people, chemotherapy with an immunotherapy medicine is the first treatment. Ivosidenib is generally considered later, if the cancer grows despite that, or if the first treatment cannot be continued. Your oncologist will explain the order for you.
Is ivosidenib available in India?
Access is limited and the situation changes. In some cases it has to be imported on a named-patient basis, or reached through a trial. Ask your oncologist to check the current position, and ask for a written, itemised estimate, because the cost is quoted separately and varies.
Does the tablet have side effects?
Yes. Tiredness, nausea and loose stools are common, and some people need heart rhythm checks. Most side effects are manageable when reported early. The targeted therapy page covers them in detail, and your team will tell you which ones mean calling the same day.
What if there was not enough tissue to test?
Ask whether a blood-based tumour DNA test is possible, or whether a repeat biopsy is reasonable. A repeat biopsy is a real procedure with its own risks, so it is weighed against how much the result would change. The tumour board can advise on this.
How do I get my report reviewed?
Bring the full molecular report, your scans on a disc and your biopsy report to a medical oncologist. Call the CION helpline if you are not sure where to start. Someone will arrange a consultation and tell you what to bring.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Bile Duct Cancer Targeted Therapy
- National Cancer Institute — Bile Duct Cancer Treatment
- Cancer Research UK — Treatment for bile duct cancer
- Cholangiocarcinoma Foundation — Resources & Support for Bile Duct Cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Why every biliary cancer should be molecularly testedWhy one broad test comes before any treatment choiceFGFR2 fusions in bile duct cancerThe other common targetable fault in this cancerHER2, BRAF and MSI in bile duct cancerThe rarer findings a gene panel can turn upIDH1 and IDH2 mutation treatmentHow the targeted tablet works and its side effects
Talk to us
Has your tumour been tested for IDH1 and the other faults?
If you are not sure whether molecular testing was done, or what your report means, a medical oncologist can go through it with you. One helpline serves every CION centre.